Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis

Eisai

Status: Completed

Conditions: Rheumatoid Arthritis

Treatments: Drug: Iguratimod

Study type: Observational

Funder types: Industry

Identifiers

NCT01850966

CRM01T

Details and patient eligibility

About

To investigate the safety and efficacy of the administration of Iguratimod (CRM01T) for 52 weeks in patients with rheumatoid arthritis in clinical practice

Enrollment: 2,747 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

• Participants with rheumatoid arthritis
• Participants who take iguratimod

Exclusion criteria

• Participants registered for this survey previously
• Pregnant women or women suspected of being pregnant
• Participants with a serious liver disorder
• Participants with peptic ulcer
• Participants with known hypersensitivity to iguratimod or any of its excipients

Trial design

2,747 participants in 1 patient group

Iguratimod

Treatment:

Drug: Iguratimod